{"filing":{"accession_number":"0001104659-26-107721","cik":"0001727196","ticker":"SRRK","company_name":"Scholar Rock Holding Corp","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"tm2625438d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926107721/tm2625438d1_8k.htm"},"events":[{"id":33503,"run_id":30805,"accession_number":"0001104659-26-107721","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Scholar Rock disclosed FDA approval of ISEMBYLD for spinal muscular atrophy, a significant regulatory and commercial milestone. The disclosure also corrects a management misstatement regarding post-marketing safety commitments, specifically pregnancy safety studies and fracture reporting requirements. This is a material operational/regulatory event involving product approval and compliance obligations, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other named types. The correction of the erroneous statement and the FDA's post-marketing requirements are operationally and commercially significant to investors.","company_name":"Scholar Rock Holding Corp","ticker":"SRRK","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36963,"accession_number":"0001104659-26-107721","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Scholar Rock disclosed FDA approval of ISEMBYLD for spinal muscular atrophy, a significant regulatory and commercial milestone. The disclosure also corrects a management misstatement regarding post-marketing safety commitments, specifically pregnancy safety studies and fracture reporting requirements. This is a material operational/regulatory event involving product approval and compliance obligations, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other named types. The correction of the erroneous statement and the FDA's post-marketing requirements are operationally and commercially significant to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:32:56.136001+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36963,"accession_number":"0001104659-26-107721","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Scholar Rock disclosed FDA approval of ISEMBYLD for spinal muscular atrophy, a significant regulatory and commercial milestone. The disclosure also corrects a management misstatement regarding post-marketing safety commitments, specifically pregnancy safety studies and fracture reporting requirements. This is a material operational/regulatory event involving product approval and compliance obligations, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other named types. The correction of the erroneous statement and the FDA's post-marketing requirements are operationally and commercially significant to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:32:56.136001+00:00","company_name":"Scholar Rock Holding Corp","ticker":"SRRK","filing_date":"2026-09-15"}]}